These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11903575)

  • 1. CD99/MIC-2 surface protein expression in breast carcinomas.
    Milanezi F; Pereira EM; Ferreira FV; Leitão D; Schmitt FC
    Histopathology; 2001 Dec; 39(6):578-83. PubMed ID: 11903575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD99 correlates with low cyclin D1, high topoisomerase 2 status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.
    Czapiewski P; Wełnicka-Jaśkiewicz M; Seroczyńska B; Skokowski J; Sejda A; Szade J; Wiewiora C; Biernat W; Żaczek A
    Pol J Pathol; 2015 Sep; 66(3):269-75. PubMed ID: 26619106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibin and CD99 (MIC2) expression in uterine stromal neoplasms with sex-cord-like elements.
    Baker RJ; Hildebrandt RH; Rouse RV; Hendrickson MR; Longacre TA
    Hum Pathol; 1999 Jun; 30(6):671-9. PubMed ID: 10374776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix-producing metaplastic breast carcinoma - a rare tumor with heterologous elements.
    Shruti S; Siraj F
    Ger Med Sci; 2017; 15():Doc17. PubMed ID: 29255401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of immunohistochemistry for CD99 in the identification of matrix-producing carcinoma of the breast.
    Walker JA; Carder PJ
    Histopathology; 2003 Mar; 42(3):300-1. PubMed ID: 12605650
    [No Abstract]   [Full Text] [Related]  

  • 6. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast.
    Safwat MD; Habib F; Elayat A; Oweiss N; Reffat S; Algaidi S
    Folia Morphol (Warsz); 2009 Aug; 68(3):144-55. PubMed ID: 19722158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
    Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs).
    Goto A; Niki T; Terado Y; Fukushima J; Fukayama M
    Histopathology; 2004 Oct; 45(4):384-92. PubMed ID: 15469477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD99 and HLA-II immunostaining in breast cancer tissue and their correlation with lymph node metastasis.
    Baccar A; Ferchichi I; Troudi W; Marrakchi R; Ben Hmida N; Jebini S; Mrad K; Ben Romdhane K; Benammar Elgaaied A
    Dis Markers; 2013; 34(5):363-71. PubMed ID: 23481630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleomorphic carcinoma of the breast: clinicopathological analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma.
    Silver SA; Tavassoli FA
    Histopathology; 2000 Jun; 36(6):505-14. PubMed ID: 10849092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p40 and laminin 332 in metaplastic spindle cell carcinoma of the breast compared with other malignant spindle cell tumours.
    D'Alfonso TM; Ross DS; Liu YF; Shin SJ
    J Clin Pathol; 2015 Jul; 68(7):516-21. PubMed ID: 25795733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM; Mentrikoski MJ; Wick MR
    Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor.
    Folpe AL; Hill CE; Parham DM; O'Shea PA; Weiss SW
    Am J Surg Pathol; 2000 Dec; 24(12):1657-62. PubMed ID: 11117787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metaplastic carcinomas of the breast (light microscopic and immunohistochemical features).
    Agrawal K; Kaur M; Bajaj P; Agrawal C; Pathania OP
    Indian J Cancer; 2001; 38(2-4):80-4. PubMed ID: 12593444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours.
    Pelosi G; Fraggetta F; Sonzogni A; Fazio N; Cavallon A; Viale G
    Virchows Arch; 2000 Sep; 437(3):270-4. PubMed ID: 11037347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD99 in pleomorphic carcinomas of the lung.
    Yoo SH; Han J; Kim TJ; Chung DH
    J Korean Med Sci; 2005 Feb; 20(1):50-5. PubMed ID: 15716602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic observation of carcinomas arising in fibroepithelial neoplasms of the breast].
    Yang G; Guo L; Jin H; Li J; Ding H
    Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):437-41. PubMed ID: 25327790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR.
    Radhi JM
    Histopathology; 2000 Feb; 36(2):156-60. PubMed ID: 10672061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.